Navigation Links
Caris Life Sciences ASCO Presentation Highlights the Utility of Molecular Profiling for the Management of Rare and Aggressive Cancers
Date:6/2/2013

IRVING, Texas, June 2, 2013 /PRNewswire/ -- Caris Life Sciences™, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present findings today at the 2013 ASCO annual meeting from the analysis of its Caris Molecular Intelligence™ database. This database examined the results of molecular profiling of both common and rare cancer types for the identification of potentially clinically actionable targets.

For the purposes of this study, 42,000 patient tumors were analyzed in total, covering 150 histological subtypes received from more than 6,400 physicians worldwide. Furthermore, 14,700 of these cases, or 35 percent of the tumors profiled, are typically categorized as "rare" tumors, a patient segment that is typically underserved by current guidelines and where molecular profiling has the potential to significantly impact patient care.  

Breaking the data down by tumor type, these findings included profiling the following tumor types:

  • 6,000-plus Ovarian cancers
  • 5,000-plus Breast cancers
  • 6,000-plus Non-small-cell lung cancers
  • 5,000-plus Colorectal cancers
  • 2,000-plus Pancreatic cancers
  • 14,000-plus Rare cancers

Caris has remained technology-agnostic in its approach to tumor profiling, employing a wide range of profiling technologies to uncover a broad array of key biomarkers, based upon review of the latest clinical literature showing correlations to known therapies. Technologies utilized for this comprehensive database included mutational analysis by Sanger Sequencing, Next-Generation Sequencing, Polymerase Chain Reaction (PCR), Gene Copy Number alterations and translocations by Fluorescent In Situ Hybridization/Chromogenic In Situ Hybridization (FISH/CISH), Methylation analysis, and protein expression by immunohistochemistry (IHC). 

"To date, Caris has profiled nearly 50,000 patients, which is the largest and most comprehensive collection of biomarker profiles in the industry today," said Zoran Gatalica , M.D., DSc, Executive Medical Director at Caris Life Sciences, and a lead researcher in this study. "This study provided critical insights into the distribution of common and rare genetic and protein alterations, with direct and potential treatment implications. Our multi-technology approach to tumor profiling has been critical to building this extensive database, as it provides the most meaningful biomarker analysis and thorough interrogation of the cancer pathways."

Daniel Von Hoff , M.D., FACP, of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz., will present results from its study, Integrating Molecular Profiling Into Cancer Treatment Decision Making: Experience With Over 35,000 Cases, at this year's ASCO annual meeting.

"Because of the size and depth of this database, these data points hold significant potential to detect rare molecular aberrations and biomarker targets in patients with common or rare cancers," said Dr. Von Hoff , Physician in Chief and Director of Translational Research at TGen; Professor of Medicine at both Mayo Clinic, Scottsdale and the University of Arizona College of Medicine; and Chief Scientific Officer at Scottsdale Healthcare and US Oncology. "The developmental and potential clinical applicability and relevance of tumor profiling is particularly compelling in cases of rare or resistant tumors, where treatment guidelines are more limited and current clinical trial data is often insufficient." Dr. Von Hoff's presentation will be held Sunday, June 2, 2013, at 8:15 a.m. at E-354 B.

About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine. This specialty oncology reference laboratory offers more than 70 clinically relevant molecular profiling tests, including its comprehensive Caris' Molecular Intelligence™ profile. Caris Molecular Intelligence correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from the world's leading clinical cancer literature. With nearly 50,000 patients profiled, this service uses the most advanced and clinically-relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company's proprietary Carisome® platform — a blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit www.carislifesciences.com.


'/>"/>
SOURCE Caris Life Sciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities
2. Caris Life Sciences Symposium to Explore Advances in Next Generation Sequencing for Gynecologic Cancers
3. Caris Life Sciences nimmt Next-Generation Sequencing zur Verbesserung des evidenzbasierten Tumorprofilierungsservices für Krebspatienten auf
4. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
5. Caris Sponsors CancerCare Connect Education Workshop on Molecular Profiling in the Treatment of Breast Cancer
6. Caris Life Sciences mejora la evaluación por perfil molecular con los biomarcadores ROS1 y MGMT-metilación
7. Caris Life Sciences Enhances Molecular Profiling Service with Addition of ROS1 and MGMT-Methylation Biomarkers
8. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
9. Data Sciences International (DSI) in Space
10. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
11. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/22/2016)... Md. , June 22, 2016  The American College ... Trade Show Executive Magazine as one of the ... on May 25-27 at the Bellagio in Las ... on the highest percentage of growth in each of the ... of exhibiting companies and number of attendees. The 2015 ACMG ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):